A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
Phillips MA., Lotharius J., Marsh K., White J., Dayan A., White KL., Njoroge JW., El Mazouni F., Lao Y., Kokkonda S., Tomchick DR., Deng X., Laird T., Bhatia SN., March S., Ng CL., Fidock DA., Wittlin S., Lafuente-Monasterio M., Benito FJG., Alonso LMS., Martinez MS., Jimenez-Diaz MB., Bazaga SF., Angulo-Barturen I., Haselden JN., Louttit J., Cui Y., Sridhar A., Zeeman A-M., Kocken C., Sauerwein R., Dechering K., Avery VM., Duffy S., Delves M., Sinden R., Ruecker A., Wickham KS., Rochford R., Gahagen J., Iyer L., Riccio E., Mirsalis J., Bathhurst I., Rueckle T., Ding X., Campo B., Leroy D., Rogers MJ., Rathod PK., Burrows JN., Charman SA.
The antimalarial drug DSM265 displays activity against blood and liver stages of Plasmodium falciparum and has a long predicted half-life in humans.